review of glp 1 GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing kidney failure. Adverse events are mostly gastrointestinal. Read IUPHAR review – Glucagon-like peptide-1

Primary Care of Clear Lake offers Semaglutide GLP-1 for weight reduction as an efficient therapy option for treating obesity through lower calorie intake and appetite control

At the same time, nearly everyone who comes in for weight loss surgery has already tried a GLP-1

This fueled an exponential growth in interest among the public, but not everyone qualifies for GLP-1s through their insurance or can afford them, even if they do

Obesity, metabolic syndrome, and musculoskeletal disease: common inflammatory pathways suggest a central role for loss of muscle Integrity

What are GLP-1s, and how do they work

Cignas Evernorth initiative) and pharmacy benefit managers are developing new tools to manage GLP-1 cost and utilization, often leveraging ePA interfaces